Validation study of predictive value of capillaroscopic skin ulcer risk index (CSURI) in scleroderma patients treated with bosentan

摘要

CSURI is a capillaroscopic index that is able to identify scleroderma (SSc) patients at high risk for new or non-healing digital ulcers (DU) in the next three months (1). CSURI has been validated, only in patients not treated with bosentan in a large multi-centre study in 2011 (1). Bosentan is an en-dothelin receptor antagonist and at present it is the only drug approved to reduce the number of new scleroderma DU in secondary prevention (2-3).The aim of the present study was to evaluate the predictive value of CSURI in SSc patients assuming bosentan for the secondary prevention of DU.